One dose of an experimental drug cover offer lifetime treatment for people with high cholesterol, but its long-term safety is ...

Q3 2025 Earnings Call Transcript November 7, 2025 Operator: Good day, and welcome to the Cidara Therapeutics Q3 2025 ...

UCSF's Chancellor Hawgood urged transition to a "Second Curve" of innovation, leveraging philanthropy, new infrastructure, ...

University of Cincinnati reported positive Phase 2 melanoma trial results, with a third of patients responding to a combined ...

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...

Researchers from Rutgers Cancer Institute, New Jersey’s only National Cancer Institute (NCI) - designated Comprehensive ...

Existing frameworks for explainable artificial intelligence (XAI) and AI governance, such as the EU AI Act and the NIST AI ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...

Sana Biotechnology, CAMP4 Therapeutics and Crinetics Pharmaceuticals have all used the third quarter to refocus their ...

The South Korean government has approved a 940.8 billion won ($645 million) programme to develop next-generation medical ...

Get the latest on MindMed’s Q3 2025 earnings: clinical trial milestones, financial strength, and pivotal Phase III data readouts expected in 2026.

Insilico announced the launch of its innovative cardiometabolic disease portfolio at BIO Europe 2025. The portfolio covers a ...